GLP-1 & Incretin Science

How a Molecule Lasts a Month Instead of a Week

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Weekly incretin dosing is achieved by binding albumin reversibly. Monthly dosing requires a different mechanism: conjugating the active peptides to a monoclonal antibody, which persists far longer because it is recycled by the neonatal Fc receptor rather than merely shielded.

Key facts

Weekly mechanism
Reversible albumin binding
Monthly mechanism
Antibody conjugation
Key receptor
Neonatal Fc receptor (FcRn)
Antibody persistence
Weeks, not hours
Example
Maridebart cafraglutide, once monthly
Phase 2 readout
NEJM, 4 September 2025

What albumin binding achieves and where it stops

A fatty acid attached to a peptide binds albumin reversibly, which prevents renal filtration and shields against proteases. That takes native GLP-1 from minutes to about a week for semaglutide. It is a shielding strategy (the peptide survives longer because it is hidden), and roughly a week is where that approach plateaus.

Why antibodies last so much longer

Not shielding but active rescue. The neonatal Fc receptor binds antibodies taken up into cells and returns them to circulation instead of allowing degradation. That recycling is why monoclonal antibodies persist for weeks: they are not merely evading clearance, they are being retrieved from it.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The conjugate idea

Attach the pharmacologically active peptides to an antibody and they inherit its pharmacokinetics. Maridebart cafraglutide does this: a monoclonal antibody against the GIP receptor, with GLP-1 receptor agonist peptides conjugated through amino-acid linkers. The antibody is not a passive carrier. It is itself one of the two pharmacological actions, but it also supplies the duration.

Why monthly dosing is worth engineering for

Adherence to any chronic treatment declines with how often it must be taken, and a self-administered weekly injection is a recurring demand. Twelve administrations a year rather than fifty-two is a different proposition, particularly for a condition requiring indefinite treatment. Whether that translates into better real-world outcomes is a separate question from whether it is pharmacologically achievable.

What long duration costs

Control. A compound with a one-week half-life is largely cleared within a month of stopping; one dosed monthly is not. If adverse effects appear, they cannot be ended promptly by withholding the next dose. Long duration is a convenience benefit and a reversibility cost, and the two are inseparable.

Regulatory position

Maridebart cafraglutide is investigational and holds no marketing authorisation anywhere. Its Phase 3 programme is ongoing. Nothing supplied here is related to it or to any licensed weight-management medicine.

Quick reference

StrategyMechanismInterval
Native GLP-1NoneMinutes
C16 palmitic (liraglutide)Weak albumin bindingDaily
C18/C20 diacidStrong albumin bindingWeekly
Antibody conjugateFcRn recyclingMonthly

Frequently asked questions

Why can't albumin binding give monthly dosing?

It is a shielding strategy with a practical ceiling around a week. Antibodies persist longer because FcRn actively retrieves them from degradation.

What is the neonatal Fc receptor?

A receptor that binds antibodies taken into cells and returns them to circulation rather than letting them be degraded. It is the basis of antibody persistence.

What is the downside of monthly dosing?

Reversibility. A long-acting compound cannot be cleared quickly by withholding the next dose if adverse effects appear.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.